Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07490431 · ClinicalTrials.gov registry record
An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States
A clinical trial, sponsored by Bayer.
- Not yet
- Registry status
- 1,500
- Enrollment target
NCT07490431: Clinical Trial study, sponsored by Bayer.
NCT07490431 is a clinical trial that has not yet begun recruiting, run by Bayer. The registered enrollment target is 1,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07490431 has not yet begun recruiting, sponsored by Bayer.
- NOT YET RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
Study Summary
Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life harder. Elinzanetant is a new, hormone free medicine that works by blocking certain signals in the brain that are linked to these symptoms. It has already been shown in clinical studies to help reduce hot flashes. This study is being done to learn about how elinzanetant is used, how well it works, and how safe it is for women with menopause symptoms in real-world, everyday medical care. The main goal is to understand who is starting treatment with elinzanetant and what symptoms they have. The study will also look at how well elinzanetant helps with hot flashes, night sweats, and sleep problems, how safe it is, how satisfied women are with the treatment, and how it affects their quality of life and daily activities. To do this, researchers will follow about 1,500 women in the United States who are starting elinzanetant as part of their usual care. Women will answer questions about their symptoms, sleep, and daily life using a secure app on their phone or computer. Some women will also wear a smart ring for a few weeks to collect information about their sleep. The study will last about 12 weeks for most women, but some will be followed for up to 2 years. No extra treatments or tests will be given as part of the study-researchers will only collect information about how women are doing while taking elinzanetant as prescribed by their own doctor. The results will help doctors and patients understand how elinzanetant works in real life and support better care for women going through menopause.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2026-11-02 |
| Est. Completion | 2029-11-02 |
What is known before NCT07490431 opens enrollment
NCT07490431 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT07490431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07490431 about?
NCT07490431 is a clinical study titled "An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States". Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life harder. Elinzanetant is a new, hormone free medicine that works by bloc...
What is the current status of trial NCT07490431?
This trial is currently not yet recruiting. The enrollment target is 1,500 participants. The study started on 2026-11-02. Estimated completion is 2029-11-02.
What interventions are being tested in trial NCT07490431?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT07490431?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI